In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Increased mortality despite successful multifactorial cardiovascular risk reduction in healthy men. 40-year follow-up of the Helsinki businessmen study intervention trial

Session Controversies in cardiovascular risk assessment and prevention

Speaker Timo Strandberg

Congress : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention - Epidemiology
  • Session type : Moderated Posters
  • FP Number : P5082

Authors : T Strandberg (Helsinki,FI)

Authors:
T. Strandberg1 , 1University of Helsinki - Helsinki - Finland ,

On behalf: Helsinki Businessmen Study Group

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1053-1054

Background: Despite a 5-year multifactorial cardiovascular disease (CVD) risk reduction in an intervention trial, mortality was unexpectedly higher in the intervention than the control group during the 15-year follow-up.

Purpose: In order to find explanations for the adverse outcome, we have extended mortality follow-up to 40 years. We have also re-examined baseline characteristics that contributed to total mortality.

Methods: The prevention period (1974–1980) included 1,222 originally healthy men (born 1919–1934) at high CVD risk, who were randomized into intervention (n=612) and control groups (n=610). The 5-year multifactorial intervention consisted of personal health education (diet, exercise, weight reduction, antismoking) and contemporary drug treatments for dyslipidemia and hypertension. In the present analysis we used previously unpublished data on baseline risk factors and lifestyle characteristics. Participants were followed-up for 40-year mortality using nation-wide death registers.

Results: The study groups were similar at baseline in 1974, and the 5-year intervention significantly improved CVD risk factors (body mass index, blood pressure, serum lipids and glucose), and total CVD risk by 46% in the intervention group. Despite this, total mortality was consistently higher in the intervention group than the control group during 25 years post-trial, but converged thereafter. Increased mortality was caused by CVD and accidental deaths. Specific factors, like drug treatments, did not explain increased mortality. Instead, of the newly-analyzed baseline factors, there was a significant interaction for mortality between intervention group and yearly vacation time (P=0.027): shorter vacation was associated with excess 30-year mortality in the intervention (hazard ratio 1.37, 95% CI 1.03–1.83, P=0.03), but not in the control group (P=0.5). This finding was robust to multivariable adjustments.

Conclusions: After a multifactorial intervention for healthy men with at least one CVD risk factor, there has been an unexpectedly increased mortality in the intervention group. This increase was especially observed in a subgroup characterized by shorter vacation time at baseline. Although this adverse response to personal preventive measures in vulnerable individuals may be characteristic to men of high social status with subclinical CVD, it clearly deserves further investigation.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are